SMi Group reports: 5th Annual 3D Cell Culture Conference in February 2022 is taking place in less than two weeks as a virtual conference In less than two weeks, SMi’s 5th Annual exclusive Conference on […]
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided a positive opinion recommending approval for Sanofi’s Dupixent (dupilumab) as an add-on maintenance therapy to treat children of […]
Rare disease-focused start-up Oak Hill Bio launched today with a pipeline of candidates acquired from multinational pharma company Takeda. Along with six of Takeda’s clinical-stage and preclinical programmes, Oak Hill Bio takes two executives with […]
Samsung Biologics has entered an agreement to acquire Biogen’s stake in the Samsung Bioepis joint venture (JV) for a total consideration of up to $2.3bn. Under the deal, Biogen is entitled to receive $1bn in […]
Sarepta Therapeutics has entered a research partnership and option agreement with GenEdit to develop gene-editing therapies for neuromuscular diseases. The alliance will leverage the NanoGalaxy platform of GenEdit and Sarepta’s gene-editing technology to develop the […]